Table 3.

Expanded Khorana risk score

Risk score
Cancer type  
 Very high risk: brain, pancreatic, gastric 
 High risk: lung, lymphoma, gynecologic, bladder, testicular, myeloma, kidney 
Hematological markers  
 Prechemotherapy platelet count ≥350 × 109/L 
 Hemoglobin count <100 g/L or use of red cell growth factors 
 Prechemotherapy leukocyte count >11 × 109/L 
Patient factor  
 Body mass index ≥35 kg/m2 
Procoagulant markers  
 D-dimer ≥ 1.44 μg/mL 
 Soluble P-selectin ≥ 53.1 ng/mL 
Risk score
Cancer type  
 Very high risk: brain, pancreatic, gastric 
 High risk: lung, lymphoma, gynecologic, bladder, testicular, myeloma, kidney 
Hematological markers  
 Prechemotherapy platelet count ≥350 × 109/L 
 Hemoglobin count <100 g/L or use of red cell growth factors 
 Prechemotherapy leukocyte count >11 × 109/L 
Patient factor  
 Body mass index ≥35 kg/m2 
Procoagulant markers  
 D-dimer ≥ 1.44 μg/mL 
 Soluble P-selectin ≥ 53.1 ng/mL 

Adapted from Ay et al.22 

Close Modal

or Create an Account

Close Modal
Close Modal